

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows

In the Claims

1. (Currently amended) A ~~conjugate~~ fusion protein comprising a first sequence and a second sequence, wherein:

the first sequence comprises an antibody or ~~antibody~~ binding fragment thereof, ~~comprising a variable region and~~ which binds to an antigen presenting cell (APC) surface molecule, wherein the APC surface molecule is selected from the group consisting of an MHC class II molecule, CD205 (DEC205), CD204, CD14, CD206, TLRs, Langerin (CD207), DC-SIGN (CD209), CD68, CD83, CD33, CD54 and BDCA-2,3,4; and

the second sequence comprises a Notch ligand or a fragment thereof, wherein the second sequence comprises a Notch ligand DSL domain and at least one EGF-like repeat, wherein the Notch ligand is selected from the group consisting of human Delta 1 comprising the amino acid sequence of SEQ ID NO: 40, human Delta 3 comprising the amino acid sequence of SEQ ID NO: 41, human Delta 4 comprising the amino acid sequence of SEQ ID NO: 42, human Jagged 1 comprising the amino acid sequence of SEQ ID NO: 43, and Jagged 2 comprising the amino acid sequence of SEQ ID NO: 44, and wherein the second sequence retains Notch signaling activity.

2-17. (Cancelled)

18. (Currently amended) The ~~conjugate~~ fusion protein according to claim 1, wherein the first sequence is an antibody or antibody fragment which binds to an MHC class II molecule.

19-28. (Cancelled)

29. (Currently amended) A ~~conjugate~~ fusion protein prepared by
(a) transforming a host cell with an expression vector comprising a polynucleotide sequence encoding the ~~conjugate~~ fusion protein of claim 1; and

(b) culturing the host cell under conditions which provide for expression of the ~~conjugate~~ fusion protein.

30. (Withdrawn) A method of targeting a protein for Notch signalling modulation, or a polynucleotide coding therefor, to an APC comprising exposing the APC to the conjugate according to claim 1.

31. (Currently amended) A composition comprising the ~~conjugate~~ fusion protein of claim 1 and a pharmaceutically acceptable excipient, diluent or carrier.

32. (Withdrawn) A method of preventing or treating a disease or infection a subject in need thereof, comprising administering the conjugate according to claim 1 to the subject.

33. (Withdrawn) The method according to claim 32, wherein the disease is a T-cell mediated disease.

34-36. (Cancelled)

37. (New) A fusion protein comprising:
an antibody or antigen binding fragment thereof which binds to an APC surface molecule selected from the group consisting of CD205 (DEC205), CD204, CD14, CD206, TLR, Langerin (CD207), DC-SIGN (CD209), CD32, CD68, CD83, CD33, CD54, BDCA-2, BDCA-3, BDCA-4, wherein the antibody or binding fragment thereof is fused to a Notch ligand or a fragment thereof comprising a Notch ligand DSL domain and at least one EGF-like repeat, wherein the Notch ligand is selected from the group consisting of human Delta1 comprising the amino acid sequence of SEQ ID NO: 40; human Delta3 comprising the amino acid sequence of SEQ ID NO: 41; human Delta4 comprising the amino acid sequence of SEQ ID NO: 42; human Jagged1 comprising the amino acid sequence of SEQ ID NO: 43; human Jagged2 comprising the amino acid sequence of SEQ ID NO: 44 and a human Notch ligand fragment selected from the group consisting of the amino acid sequence of SEQ ID NO: 25, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 36, SEQ ID NO: 38 and SEQ ID NO: 39.